Founders
Sourav Sinha
Oncolinx
The next generation of cancer therapies.
From
Boston, MA
Founded
2013
Oncolinx, in conjunction with the National Cancer Institute, is developing antibody-drug conjugates (ADCs) that carry a patented, immune-activating drug payload called Azonafide exclusively to cancer cells. The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world – concurrently developing ADCs across 30 different cancer indications.
